Davis Rea LTD. acquired a new stake in CannTrust Holdings Inc (NYSE:CTST) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 496,135 shares of the company’s stock, valued at approximately $3,846,000. CannTrust makes up approximately 2.3% of Davis Rea LTD.’s investment portfolio, making the stock its 20th largest position. Davis Rea LTD. owned approximately 0.47% of CannTrust as of its most recent SEC filing.
A number of equities research analysts have recently issued reports on CTST shares. Bloom Burton reaffirmed an “accumulate” rating on shares of CannTrust in a research note on Friday, March 29th. Zacks Investment Research cut shares of CannTrust from a “buy” rating to a “hold” rating in a research note on Wednesday, April 3rd.
CTST traded down C$0.44 during trading on Thursday, hitting C$7.03. 2,261,426 shares of the stock traded hands, compared to its average volume of 1,165,646. The stock has a market capitalization of $789.13 million, a P/E ratio of -63.91 and a beta of 4.40. The company has a quick ratio of 5.54, a current ratio of 7.65 and a debt-to-equity ratio of 0.06. CannTrust Holdings Inc has a 12-month low of C$4.35 and a 12-month high of C$11.97.
CannTrust (NYSE:CTST) last announced its quarterly earnings results on Thursday, March 28th. The company reported C($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.04) by C($0.16). The firm had revenue of C$16.20 million for the quarter, compared to analysts’ expectations of C$20.99 million. CannTrust had a negative net margin of 28.09% and a negative return on equity of 7.34%. CannTrust’s quarterly revenue was up 131.4% on a year-over-year basis. Sell-side analysts expect that CannTrust Holdings Inc will post 0.03 EPS for the current fiscal year.
CannTrust Company Profile
CannTrust Holdings Inc produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital.
Recommended Story: Are analyst ratings accurate?
Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.